Literature DB >> 32474518

Targeting EZH2 depletes LMP1-induced activated regulatory T cells enhancing antitumor immunity in nasopharyngeal carcinoma.

Wei Sun1, Lin Chen1, Jun Tang2, Chengcheng Zhang1, Yihui Wen1, Weiping Wen1.   

Abstract

OBJECTIVE: Regulatory T cells (Tregs) are critical factors that impair antitumor immunity. Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) is one of the most pathogenic factors in nasopharyngeal carcinoma (NPC). However, the role of EBV-encoded LMP1 in regulating Treg generation in NPC remains unclear.
MATERIALS AND METHODS: The in vitro stability of activated Tregs (aTregs) influenced by LMP1 was analyzed by flow cytometry. The inhibitory effects of LMP1-HONE1 antigen-induced aTregs on tumor-associated antigen (TAA)-specific T cells were analyzed in vitro and in vivo. Finally, the expression of LMP1, Foxp3, and enhancer of zeste homolog 2 (EZH2) were analyzed in samples from 86 NPC patients by immunohistochemistry and immunofluorescence.
RESULTS: LMP1 upregulated the expression of EZH2, which increased the stability of aTregs in vitro. EZH2 inhibitor, DZnep, depleted LMP1-HONE1 antigen-induced aTregs in vitro and led to potent TAA-specific T cell antitumor immunity in vivo. In NPC tissues, LMP1 expression level was positively correlated with the number of EZH2+ Tregs, which was positively correlated with clinical stage and overall survival.
CONCLUSIONS: EZH2 is essential for maintaining the stability and inhibitory functions of aTregs that are induced by EBV-encoded LMP1 in NPC.

Entities:  

Keywords:  Enhancer of zeste homolog 2; immunity; latent membrane protein 1; nasopharyngeal carcinoma; regulatory T cells

Mesh:

Substances:

Year:  2020        PMID: 32474518     DOI: 10.4103/jcrt.JCRT_986_19

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

1.  Identification of key pseudogenes in nasopharyngeal carcinoma based on RNA-Seq analysis.

Authors:  Xiujuan Zhang; Xiaole Song; Yuting Lai; Bijun Zhu; Jiqin Luo; Hongmeng Yu; Yiqun Yu
Journal:  BMC Cancer       Date:  2021-04-30       Impact factor: 4.430

2.  The association between lncRNA H19 and EZH2 expression in patients with EBV-positive laryngeal carcinoma.

Authors:  Irina E Hotoboc; Alina Fudulu; Raluca Grigore; Serban Bertesteanu; Irina Huica; Iulia V Iancu; Anca Botezatu; Coralia Bleotu; Gabriela Anton
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-11-26       Impact factor: 2.124

Review 3.  Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.

Authors:  Enyong Dai; Zhi Zhu; Shudipto Wahed; Zhaoxia Qu; Walter J Storkus; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2021-12-20       Impact factor: 41.444

Review 4.  Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.

Authors:  Haihua Wang; Weiyuan Wang; Songqing Fan
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

Review 5.  Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis.

Authors:  Shimaa Hassan AbdelAziz Soliman; Arturo Orlacchio; Fabio Verginelli
Journal:  Microorganisms       Date:  2021-05-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.